NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

Published facts

What the notice says

Buyer

NHS England

Published status

complete

Latest release reference

043951-2025

CPV codes

Common Procurement Vocabulary (CPV) codes: 33600000

Published tags

award, contract

Latest record Bidwake loaded from this source

27 Aug 2026

NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025<br/>CM/PHR/24/5680/01 - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 <br/>CM/PHR/24/5680/02 - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026

Open the official Find a Tender notice

Observed notice trail

How the published record developed

Events follow the publisher date where one is available. “Seen by Bidwake” is the date this service first found the record.

1. Award notice observed

   29 Jul 2025

   Latest variant observed by Bidwake on 16 Jul 2026.

   Open this official Find a Tender notice

   Record references

   Release reference

   043951-2025

   Published tags

   award, contract

Awards and suppliers

Published award and contract facts

• NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

  Buyer: NHS EnglandSupplier: Biogen Ltd.

  End date in notice

  Date not published

  Value shown in notice

  £1Value from the linked contract

  Official source

  Open the official Find a Tender notice for NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

  About this figure

  • This figure comes from the linked contract record. Overall totals continue to use the separately published award value.

  View record references

  Source

  Find a Tender

  Award or lot reference

  043951-2025-1

• NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

  Buyer: NHS EnglandSupplier: GlaxoSmithKline UK Limited

  End date in notice

  Date not published

  Value shown in notice

Related evidence

Published terms and linked processes

• Options are statedLot 1

  With an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

  Published 29 Jul 2025.Open supporting notice 043951-2025
• Options are statedLot 2

  With an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.

  Published 29 Jul 2025.Open supporting notice 043951-2025

No exact source-published process relationship was found.